Tag: Erlotinib,In the News,NSCLC,Non-Small Cell Lung Cancer,Veristrat,Xconomy,cancer diagnostics,chemotherapy,liquid biopsy,lung cancer,molecular diagnostic,oncology,personalized medicine

Biodesix, a Boulder, CO-based company that develops molecular diagnostic tests, said today that it has passed a key clinical trial that shows its VeriStrat test can give physicians a better idea of what to do next after the first round of treatment for non-small cell lung cancer has failed.